Immunotherapy News
Tumor antigens key to improving cancer immunotherapy study Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients. Friday, November 17th, 2023 |
|
Project seeks new way to assess immunotherapy effectiveness GE Healthcare has awarded researchers $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course. Thursday, November 7th, 2019 |
|
New prostate cancer treatment concept Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer. Friday, August 30th, 2019 |
|
Encephalitis identified as rare toxicity of immunotherapy treatment Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies. Monday, July 22nd, 2019 |
|
Breast cancer-killing RIG A recent study in the journal Cancer Research demonstrates that a RIG-I agonist has potent immunogenic and therapeutic effects in breast cancer. Friday, December 14th, 2018 |
|
Combination therapy improves small-cell lung cancer survival Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine. Friday, October 26th, 2018 |
|
Research conducted by medical students recognized at events Vanderbilt-Ingram Cancer Center, Meharry Medical College and Tennessee State University Cancer Partnership recently hosted the 2018 annual retreat and poster contest, “Health Disparities in Cancer Immunology & Immune Therapy.” Monday, March 12th, 2018 |
|
Study to test combination therapy for breast cancer Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer. Friday, October 27th, 2017 |
|
V Foundation grants bolster cancer initiatives Two Vanderbilt-Ingram Cancer Center (VICC) investigators have earned grant awards from The V Foundation for Cancer Research, continuing the foundation’s support for innovative cancer research initiatives at VICC. Raymond Blind, Ph.D. Thursday, November 17th, 2016 |
|
Study details rare heart risk of certain cancer therapies Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of […] Monday, November 7th, 2016 |
|
VICC treats first patient in Tennessee with novel cellular immunotherapy For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […] Monday, February 29th, 2016 |